Tim Rolph

Loss-of-function mutations in SLC30A8 protect against type 2 diabetes

Jason Flannick, Nicola L. Beer, Suzanne B.R. Jacobs et al. · Nature Genetics · 2014 · 488 citations · Full text

Genetics, Diabetes, Type 2 +4

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Saswata Talukdar, Yingjiang Zhou, Dongmei Li et al. · Cell Metabolism · 2016 · 477 citations · Full text

Obesity, Metabolic Syndrome, Long-acting Fgf21 Molecule +12

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Stephen A. Harrison, Peter Ruane, B. Freilich et al. · Nature Medicine · 2021 · 320 citations

Hepatology, Liver Physiology, Pharmacology +4

Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export

Phillip J. White, Amanda L. Lapworth, Jie An et al. · Molecular Metabolism · 2016 · 264 citations · Full text

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Stephen A. Harrison, Juan P. Frías, Guy Neff et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 198 citations

Medicine, Non-alcoholic Steatohepatitis, Pharmacotherapy +3